Chrysos Corp. Ltd. · ASX:C79
Chrysos — Shareholder Meeting (November 2022)
16 slides from Chrysos's shareholder meeting presentation, Nov 28, 2022
Slide 1: Faster, more accurate gold analysis
For personal use only Faster, more accurate gold analysis 2022 Annual General Meeting 28 November 2022 Rob Adamson, Chair Dirk Treasure, Managing Director and CEO
Slide 2: Important notice
Important notice For personal use only The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) (“Chrysos” or the “Group") and is general background information about Chrysos’ current activities as at the date of this presentation. The information is given in sum
Slide 3: Agenda
Agenda For personal use only 01 Chair Address 02 Managing Director Address 03 Formal business 04 Questions & Answers
Slide 4: Chair Address
For personal use only Chair Address [Insert] Rob Adamson
Slide 5: Experienced leadership team
Experienced leadership team Supported by a well respected and tenured board For personal use only Senior leadership team Board of Directors Dirk Treasure Rob Adamson Kerry Gleeson Founding CEO & Managing Director Founder & Chairman Director • Metallurgist with a background in both • 20+ years’ exper
Slide 6: The Chrysos Vision
The Chrysos Vision To become the world’s leading provider of innovative assay services and technologies For personal use only Market Challenge: Traditional assay techniques are slow, labour intensive, complex, destructive to the assay sample, and involve Fully-quantitative analysis in as little as 2
Slide 7: Managing Director Address
For personal use only Managing [Insert] Director Address Dirk Treasure, Managing Director and CEO
Slide 8: Chrysos – revolutionising the global mining industry
Chrysos – revolutionising the global mining industry Chrysos is a global provider of novel assay services through its proprietary PhotonAssayTM technology For personal use only Disruptive Minerals Analysis Lease and Service Model with Industry Accepted Technology Technology Tier 1 Counterparties Dis
Slide 9: Large & unpenetrated TAM
Large & unpenetrated TAM Chrysos has established a global structure to sustain rapid international growth For personal use only Existing PhotonAssayTM Reach TAM for PhotonAssayTM Units 700 610 Units 600 500 PhotonAssayTM Unit 400 410 On-site Laboratories +561 Units 300 Units 200 100 200 Off-site Lab
Slide 10: FY22 highlights
FY22 highlights Strong growth ahead of Prospectus forecasts For personal use only $14.3m $1.45m $558m Total Revenue in FY22 Proforma EBITDA in FY221 Total Contract Value (TCV) • +215% growth on FY21 (+$4.5m) • +$2.2m growth on FY21 (-$0.7m) • +$147m in TCV added post period ($705m)2 • +3.8% increase
Slide 11: Q1 FY23: Financial and operating highlights
Q1 FY23: Financial and operating highlights Q1 FY23 unaudited Total Revenue of $5.1m, reflecting 9% growth on the previous Quarter For personal use only $5.1m 740k $703m Total Unaudited Revenue Samples processed Total Contract Value (TCV) • +9% growth on Q4 FY22 of $4.7m • Increased +14% on Q4 FY22
Slide 12: Sustained revenue growth
Sustained revenue growth New unit deployments and continued strong utilisation are driving revenue growth For personal use only Unaudited MMAP, AAC & Other Income ■ Minimum Monthly Assay Payments (MMAP) provide sustainable, 6,000 forecastable minimum revenue ■ Q1 FY23 MMAP was $3.8m, up 12% on Q4 FY
Slide 13: An environmentally-friendly solution
An environmentally-friendly solution Substantially better for the environment and significantly safer than fire assay For personal use only PhotonAssayTM has a substantial positive environmental impact that will continue to grow in tandem with the uptake of the technology ✓ PhotonAssayTM reduces CO2
Slide 14: Clear growth pathway
Clear growth pathway Clear organic growth plan with potential to expand TAM through additional commodities For personal use only Business Development Pipeline Multi-commodity Assaying ■ Global networks of laboratories Potential to expand TAM Potential to increase profitability Intertek ALS SGS MSALA
Slide 15: Looking ahead
Looking ahead Chrysos is well positioned to continue accelerating its global growth For personal use only ■ Strong and sustainable growth expected in FY23 ■ On track to meet FY23 Prospectus Revenue target of $26.6m, and EBITDA of $3.2m ■ 49 contracted units, with deployments extending into 2025 ■ 14
Slide 16: Thank you
For personal use only Thank you For more information, please visit chrysoscorp.com or contact us at investors@chrysoscorp.com